Herpes simplex virus infections of the newborn
- 50 Downloads
Herpes simplex virus (HSV) infection in newborns is an important cause of death and permanent neurodevelopmental disability among young children. Neonatal HSV infections can be categorized as 1) mucocutaneous (skin-eyes-mouth), 2) disseminated, or 3) encephalitic. In addition, congenital HSV infection, a distinct clinical syndrome, accounts for approximately 5% of HSV infections identified in the neonatal period. Polymerase chain reaction greatly enhances the clinician’s ability to diagnosis HSV infections, but as many as 25% of infants with neonatal HSV encephalitis have negative polymerase chain reaction studies of cerebrospinal fluid. Infants with proven or suspected HSV infections should receive acyclovir 60 mg/kg/day divided every 8 hours for 14 days if disease is restricted to the skin, eyes, or mucous membranes and for 21 days if the infant has disseminated infection or encephalitis. The benefit of long-term suppression therapy after completion of the initial treatment regimen has not been established definitively. Despite therapy with acyclovir, the best available anti-HSV drug, a substantial number of HSV-infected infants with disseminated infections or encephalitis die or have long-term neurodevelopmental sequelae.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 8.Kimberlin DW, Lin C-Y, Jacobs RF, et al.: Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001, 108:223–229. This article provides a useful clinical perspective regarding the natural history of neonatal infections after the widespread use of acyclovir. The conclusions emphasize that “no progress” was made in shortening the interval between the onset of symptoms suggesting HSV and the initiation of antiviral therapy.PubMedCrossRefGoogle Scholar
- 11.Grose C: Congenital infections caused by varicella zoster virus and herpes simplex virus. Sem Pediatr Neurol 1994, 1:43–49.Google Scholar
- 14.Kimberlin DW: Herpes simplex virus, meningitis encephalitis in the neonate. Herpes 2004, 11(suppl 2):65–76. This review summarizes in detail the current status of diagnosis, therapy, and prevention of neonatal HSV infections.Google Scholar
- 17.Kimberlin DW, Lin C-Y, Jacobs RF, et al.: Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001, 108:230–238. This comprehensive manuscript confirms the value of high dose acyclovir in the management of neonatal HSV infections. High dose therapy (60 mg/kg/day) was associated with reduced morbidity and mortality when compared with the previous regimen of 30 mg/kg/day.PubMedCrossRefGoogle Scholar
- 18.Brown ZA, Wald A, Morrow RA, et al.: Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003, 289:203–209. This prospective study confirmed that cesarean section reduces the risk of HSV transmission from infected mother to newborn infant. Risk factors for neonatal HSV infection in this study included first episode of infection, HSV isolation from the cervix, HSV isolation at the time of labor, invasive monitoring of the infant, delivery before 38 weeks, and maternal age less than 21 years.PubMedCrossRefGoogle Scholar
- 22.Kimberlin DW, Powell D, Gruber W, et al.: Administration of oral acyclovir suppressive therapy after neonatal herpes simplex disease limited to skin, eyes, and mouth: results of a phase I/II trial. Pediatr Infect Dis J 1996, 15:247–254. This NIAID-CASG study reported the effects of oral acyclovir suppressive therapy (300 mg/m2/dose twice or three times daily) for six months in infants with virologically confirmed HSV-2 SEM infections. Nineteen percent of the treated infants had recurrences of skin lesions compared with historical controls in which 46% of untreated infants had skin recurrences. Nearly 50% of the treated infants experienced neutropenia (ANC <1000/μL). One child shed an HSV isolate that was highly resistant to acyclovir after six months of therapy.PubMedCrossRefGoogle Scholar